Prognostic and Predictive Significance of Ki67 in Primary Non-metastatic or Recurrent Acral Melanoma: Evidence from a Multicenter Retrospective Study
View abstract on PubMed
Summary
This summary is machine-generated.High Ki67 levels in acral melanoma (AM) correlate with worse outcomes and adverse features. Routine Ki67 evaluation is recommended for improved prognostic prediction and risk stratification in AM patients.
Area Of Science
- Oncology
- Dermatology
- Pathology
Background
- Acral melanoma (AM) is a distinct subtype of cutaneous melanoma.
- Prognostic markers are crucial for managing AM patients.
Purpose Of The Study
- To investigate the prognostic significance of Ki67 expression in primary and recurrent acral melanoma.
- To assess the association of Ki67 with clinicopathological features and patient survival.
Main Methods
- Retrospective analysis of Ki67 values in primary (pKi67) and recurrent (rKi67) lesions from 481 and 97 AM patients, respectively.
- Correlation of pKi67 and rKi67 with clinicopathological variables and survival outcomes (overall survival, recurrence-free survival, survival after recurrence).
Main Results
- High pKi67 was associated with ulceration, advanced tumor stage (pT4), lymph node metastasis, and recurrence.
- Elevated pKi67 and rKi67 levels significantly correlated with poorer 5-year overall survival, recurrence-free survival, and survival after recurrence.
- Multivariate analysis confirmed Ki67 as an independent prognostic factor for survival outcomes in both primary and recurrent AM.
Conclusions
- Ki67 expression is a significant independent prognostic marker in acral melanoma.
- High Ki67 values indicate adverse pathological and prognostic features.
- Routine Ki67 assessment is recommended for enhanced risk stratification and prognostic prediction in AM.

